Propofol, a general anesthetic, has been suggested to be effective for the treatment of
migraine headaches in adults when used in subanesthetic doses (lower doses than those used
for anesthesia or sedation). Initial retrospective review of the investigators experience
with propofol for migraine in children suggests that it is safe and may be more effective
than standard treatments used in the emergency department. The investigators retrospective
series had a small subject population and a larger study is needed to compare propofol to
current available treatments.
Standard treatment currently consists of a "cocktail" of medications that include anti-nausea
medicines (metoclopramide and diphenhydramine) and an analgesic (ketorolac) as well as
intravenous fluids. Subjects assigned to the experimental group (Propofol) will receive the
same intravenous fluids and up to five doses of propofol. All subjects will undergo
assessment of their pain (self-rated on a scale from 0-10) before and after treatment.
Post-visit clinical data will be collected from the subject's medical record and subjects
will be called by telephone 24-48 hours after discharge from the emergency department to ask
how they are doing and whether they required any additional treatments such as home
medications or by other medical professionals other than OHSU.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
